NCT05695391: An ongoing trial by Laboratoire français de Fractionnement et de Biotechnologies
This trial is ongoing. It must report results 5 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05695391 |
|---|---|
| Title | A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 7, 2024 |
| Completion date | June 1, 2025 |
| Required reporting date | June 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |